EDUCATION

Medical School

  • Tufts University School of Medicine , 1990 , Boston , MA

Internship

Pediatrics
  • Boston Children's Hospital , 1991 , Boston , MA

Residency

  • Boston Children's Hospital , 1993 , Boston , MA

Fellowship

Pediatric Infectious Diseases; Pediatric Emergency Medicine
  • Boston Children's Hospital , 1996 , Boston , MA

CERTIFICATIONS

  • American Board of Pediatrics, Infectious Diseases

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Induction of T Cell Responses by Vaccination of a Streptococcus pneumoniae Whole-Cell Vaccine. Methods Mol Biol. 2022; 2410:345-355. View abstract
  2. Robust Immune Response Induced by Schistosoma mansoni TSP-2 Antigen Coupled to Bacterial Outer Membrane Vesicles. Int J Nanomedicine. 2021; 16:7153-7168. View abstract
  3. Optimization of Expression and Purification of Schistosoma mansoni Antigens in Fusion with Rhizavidin. Mol Biotechnol. 2021 Nov; 63(11):983-991. View abstract
  4. Analysis of Staphylococcus aureus Transcriptome in Pediatric Soft Tissue Abscesses and Comparison to Murine Infections. Infect Immun. 2021 03 17; 89(4). View abstract
  5. Prospective cohort study of children with suspected SARS-CoV-2 infection presenting to paediatric emergency departments: a Paediatric Emergency Research Networks (PERN) Study Protocol. BMJ Open. 2021 01 15; 11(1):e042121. View abstract
  6. Overview of the Nontyphoidal and Paratyphoidal Salmonella Vaccine Pipeline: Current Status and Future Prospects. Clin Infect Dis. 2020 07 29; 71(Suppl 2):S151-S154. View abstract
  7. A Phase 1 Randomized, Placebo-controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of Inactivated Streptococcus pneumoniae Whole-cell Vaccine in Adults. Pediatr Infect Dis J. 2020 04; 39(4):345-351. View abstract
  8. Process intensification for production of Streptococcus pneumoniae whole-cell vaccine. Biotechnol Bioeng. 2020 06; 117(6):1661-1672. View abstract
  9. Generation of protective pneumococcal-specific nasal resident memory CD4+ T cells via parenteral immunization. Mucosal Immunol. 2020 01; 13(1):172-182. View abstract
  10. Effect of a pneumococcal whole cell vaccine on influenza A-induced pneumococcal otitis media in infant mice. Vaccine. 2019 06 06; 37(26):3495-3504. View abstract
  11. Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccination. Elife. 2018 12 28; 7. View abstract
  12. Introduction of New Journal Section-Translational Medicine. Pediatr Infect Dis J. 2018 11; 37(11):1175. View abstract
  13. Th17 responses to pneumococcus in blood and adenoidal cells in children. Clin Exp Immunol. 2019 02; 195(2):213-225. View abstract
  14. Screening for Th17-Dependent Pneumococcal Vaccine Antigens: Comparison of Murine and Human Cellular Immune Responses. Infect Immun. 2018 11; 86(11). View abstract
  15. Protection against Staphylococcus aureus Colonization and Infection by B- and T-Cell-Mediated Mechanisms. mBio. 2018 10 16; 9(5). View abstract
  16. Evaluation of the Role of stat3 in Antibody and TH17-Mediated Responses to Pneumococcal Immunization and Infection by Use of a Mouse Model of Autosomal Dominant Hyper-IgE Syndrome. Infect Immun. 2018 05; 86(5). View abstract
  17. The immunological mechanisms that control pneumococcal carriage. PLoS Pathog. 2017 12; 13(12):e1006665. View abstract
  18. A Combination of Recombinant Mycobacterium bovis BCG Strains Expressing Pneumococcal Proteins Induces Cellular and Humoral Immune Responses and Protects against Pneumococcal Colonization and Sepsis. Clin Vaccine Immunol. 2017 Oct; 24(10). View abstract
  19. The Pneumococcal Type 1 Pilus Genes Are Thermoregulated and Are Repressed by a Member of the Snf2 Protein Family. J Bacteriol. 2017 08 01; 199(15). View abstract
  20. Antibody-mediated protection against Staphylococcus aureus dermonecrosis and sepsis by a whole cell vaccine. Vaccine. 2017 07 05; 35(31):3834-3843. View abstract
  21. Recombinant BCG expressing a PspA-PdT fusion protein protects mice against pneumococcal lethal challenge in a prime-boost strategy. Vaccine. 2017 03 23; 35(13):1683-1691. View abstract
  22. IL-17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccine. Vaccine. 2017 03 01; 35(9):1306-1315. View abstract
  23. Heterozygosity for transmembrane activator and calcium modulator ligand interactor A144E causes haploinsufficiency and pneumococcal susceptibility in mice. J Allergy Clin Immunol. 2017 Apr; 139(4):1293-1301.e4. View abstract
  24. Rationale and prospects for novel pneumococcal vaccines. Hum Vaccin Immunother. 2016; 12(2):383-92. View abstract
  25. Capsular Polysaccharide (CPS) Release by Serotype 3 Pneumococcal Strains Reduces the Protective Effect of Anti-Type 3 CPS Antibodies. Clin Vaccine Immunol. 2016 02; 23(2):162-7. View abstract
  26. Effect of Serotype on Pneumococcal Competition in a Mouse Colonization Model. mBio. 2015 Sep 15; 6(5):e00902-15. View abstract
  27. T(H)17-Mediated Protection against Pneumococcal Carriage by a Whole-Cell Vaccine Is Dependent on Toll-Like Receptor 2 and Surface Lipoproteins. Clin Vaccine Immunol. 2015 Aug; 22(8):909-16. View abstract
  28. Effect of nonheme iron-containing ferritin Dpr in the stress response and virulence of pneumococci. Infect Immun. 2014 Sep; 82(9):3939-47. View abstract
  29. The classical lancefield antigen of group a Streptococcus is a virulence determinant with implications for vaccine design. Cell Host Microbe. 2014 Jun 11; 15(6):729-740. View abstract
  30. Toll-like receptor 2-dependent protection against pneumococcal carriage by immunization with lipidated pneumococcal proteins. Infect Immun. 2014 May; 82(5):2079-86. View abstract
  31. Development of a whole cell pneumococcal vaccine: BPL inactivation, cGMP production, and stability. Vaccine. 2014 Feb 19; 32(9):1113-20. View abstract
  32. Immunisation against meningococcus B. Lancet. 2013 Sep 07; 382(9895):857. View abstract
  33. Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity. Proc Natl Acad Sci U S A. 2013 Aug 13; 110(33):13564-9. View abstract
  34. Toll-like receptor (TLR) 2 mediates inflammatory responses to oligomerized RrgA pneumococcal pilus type 1 protein. J Biol Chem. 2013 Jan 25; 288(4):2665-75. View abstract
  35. Distinct effects on diversifying selection by two mechanisms of immunity against Streptococcus pneumoniae. PLoS Pathog. 2012; 8(11):e1002989. View abstract
  36. Identification of protective pneumococcal T(H)17 antigens from the soluble fraction of a killed whole cell vaccine. PLoS One. 2012; 7(8):e43445. View abstract
  37. Meta-analysis of bacterial meningitis score validation studies. Arch Dis Child. 2012 Sep; 97(9):799-805. View abstract
  38. Broad antibody and T cell reactivity induced by a pneumococcal whole-cell vaccine. Vaccine. 2012 Jun 19; 30(29):4316-22. View abstract
  39. Streptococcus pneumoniae carriage in the Gaza strip. PLoS One. 2012; 7(4):e35061. View abstract
  40. Characterization of Th17 responses to Streptococcus pneumoniae in humans: comparisons between adults and children in a developed and a developing country. Vaccine. 2012 Jun 06; 30(26):3897-907. View abstract
  41. A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi. Vaccine. 2012 May 14; 30(23):3405-12. View abstract
  42. Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity. Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3623-7. View abstract
  43. B cell-intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice. Blood. 2012 Mar 22; 119(12):2819-28. View abstract
  44. An epigenetic switch mediates bistable expression of the type 1 pilus genes in Streptococcus pneumoniae. J Bacteriol. 2012 Mar; 194(5):1088-91. View abstract
  45. Characterisation of regulatory T cells in nasal associated lymphoid tissue in children: relationships with pneumococcal colonization. PLoS Pathog. 2011 Aug; 7(8):e1002175. View abstract
  46. Expression of the type 1 pneumococcal pilus is bistable and negatively regulated by the structural component RrgA. Infect Immun. 2011 Aug; 79(8):2974-83. View abstract
  47. Next generation pneumococcal vaccines. Curr Opin Immunol. 2011 Jun; 23(3):407-13. View abstract
  48. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011 Dec 03; 378(9807):1962-73. View abstract
  49. T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe. 2011 Feb 17; 9(2):158-65. View abstract
  50. Low risk of bacterial meningitis in children with a positive enteroviral polymerase chain reaction test result. Clin Infect Dis. 2010 Nov 15; 51(10):1221-2. View abstract
  51. GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine. 2010 Nov 03; 28(47):7468-75. View abstract
  52. Re-emergence of the type 1 pilus among Streptococcus pneumoniae isolates in Massachusetts, USA. Vaccine. 2010 Jul 05; 28(30):4842-6. View abstract
  53. Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol. 2010 Jun; 17(6):1005-12. View abstract
  54. Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development. J Mol Med (Berl). 2010 Feb; 88(2):135-42. View abstract
  55. The role of complement in innate and adaptive immunity to pneumococcal colonization and sepsis in a murine model. Vaccine. 2010 Jan 08; 28(3):681-5. View abstract
  56. Parental Staphylococcus aureus carriage is associated with staphylococcal carriage in young children. Pediatr Infect Dis J. 2009 Nov; 28(11):960-5. View abstract
  57. Mechanisms in the serotype-independent pneumococcal immunity induced in mice by intranasal vaccination with the cell wall polysaccharide. Microb Pathog. 2009 Sep; 47(3):177-82. View abstract
  58. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog. 2009 Jun; 5(6):e1000476. View abstract
  59. Diagnostic value of immature neutrophils (bands) in the cerebrospinal fluid of children with cerebrospinal fluid pleocytosis. Pediatrics. 2009 Jun; 123(6):e967-71. View abstract
  60. The pneumococcal pilus predicts the absence of Staphylococcus aureus co-colonization in pneumococcal carriers. Clin Infect Dis. 2009 Mar 15; 48(6):760-3. View abstract
  61. Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide. Infect Immun. 2009 May; 77(5):2076-83. View abstract
  62. Micro-geographic risk factors for malarial infection. Malar J. 2009 Feb 13; 8:27. View abstract
  63. Cerebrospinal fluid pleocytosis in children in the era of bacterial conjugate vaccines: distinguishing the child with bacterial and aseptic meningitis. Pediatr Emerg Care. 2009 Feb; 25(2):112-7; quiz 118-20. View abstract
  64. Impaired innate and adaptive immunity to Streptococcus pneumoniae and its effect on colonization in an infant mouse model. Infect Immun. 2009 Apr; 77(4):1613-22. View abstract
  65. Vitamin D3 deficiency enhances contact hypersensitivity in male but not in female mice. Cell Immunol. 2009; 255(1-2):33-40. View abstract
  66. Effect of antibiotic pretreatment on cerebrospinal fluid profiles of children with bacterial meningitis. Pediatrics. 2008 Oct; 122(4):726-30. View abstract
  67. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog. 2008 Sep 19; 4(9):e1000159. View abstract
  68. Does pneumococcal conjugate vaccine influence Staphylococcus aureus carriage in children? Clin Infect Dis. 2008 Jul 15; 47(2):289-91; author reply 291-2. View abstract
  69. Epidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriage. J Infect Dis. 2008 Jun 01; 197(11):1511-8. View abstract
  70. Children with bacterial meningitis presenting to the emergency department during the pneumococcal conjugate vaccine era. Acad Emerg Med. 2008 Jun; 15(6):522-8. View abstract
  71. Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4+ T cells. Infect Immun. 2008 Jun; 76(6):2678-84. View abstract
  72. In vitro bactericidal activity of Streptococcus pneumoniae and bactericidal susceptibility of Staphylococcus aureus strains isolated from cocolonized versus noncocolonized children. J Clin Microbiol. 2008 Feb; 46(2):747-9. View abstract
  73. Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infect Immun. 2007 Nov; 75(11):5460-4. View abstract
  74. Serum antipneumococcal antibodies and pneumococcal colonization in adults with chronic obstructive pulmonary disease. J Infect Dis. 2007 Sep 15; 196(6):928-35. View abstract
  75. SpxB is a suicide gene of Streptococcus pneumoniae and confers a selective advantage in an in vivo competitive colonization model. J Bacteriol. 2007 Sep; 189(18):6532-9. View abstract
  76. Association of the pneumococcal pilus with certain capsular serotypes but not with increased virulence. J Clin Microbiol. 2007 Jun; 45(6):1684-9. View abstract
  77. A novel role for IkappaB kinase (IKK) alpha and IKKbeta in ERK-dependent up-regulation of MUC5AC mucin transcription by Streptococcus pneumoniae. J Immunol. 2007 Feb 01; 178(3):1736-47. View abstract
  78. Clinical prediction rule for identifying children with cerebrospinal fluid pleocytosis at very low risk of bacterial meningitis. JAMA. 2007 Jan 03; 297(1):52-60. View abstract
  79. Recombinant bactericidal/permeability-increasing protein rBPI21 protects against pneumococcal disease. Infect Immun. 2007 Jan; 75(1):342-9. View abstract
  80. Interference between Streptococcus pneumoniae and Staphylococcus aureus: In vitro hydrogen peroxide-mediated killing by Streptococcus pneumoniae. J Bacteriol. 2006 Jul; 188(13):4996-5001. View abstract
  81. Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect Immun. 2006 Apr; 74(4):2187-95. View abstract
  82. c-Jun kinase is a critical signaling molecule in a neonatal model of group B streptococcal sepsis. J Immunol. 2006 Mar 01; 176(5):3181-8. View abstract
  83. Antibodies to conserved pneumococcal antigens correlate with, but are not required for, protection against pneumococcal colonization induced by prior exposure in a mouse model. Infect Immun. 2005 Oct; 73(10):7043-6. View abstract
  84. The apoptotic response to pneumolysin is Toll-like receptor 4 dependent and protects against pneumococcal disease. Infect Immun. 2005 Oct; 73(10):6479-87. View abstract
  85. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci U S A. 2005 Mar 29; 102(13):4848-53. View abstract
  86. Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease? PLoS Med. 2005 Jan; 2(1):e15. View abstract
  87. Cerebrospinal latex agglutination fails to contribute to the microbiologic diagnosis of pretreated children with meningitis. Pediatr Infect Dis J. 2004 Aug; 23(8):786-8. View abstract
  88. Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant. Infect Immun. 2004 Jul; 72(7):4290-2. View abstract
  89. Development of a model of focal pneumococcal pneumonia in young rats. J Immune Based Ther Vaccines. 2004 Jan 23; 2(1):2. View abstract
  90. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci U S A. 2003 Feb 18; 100(4):1966-71. View abstract
  91. A new prognostic scoring system for meningococcal septic shock in children: comparison with three other scoring systems. Intensive Care Med. 2003 Feb; 29(2):333; author reply 334. View abstract
  92. Factors associated with adverse outcomes in children with diabetic ketoacidosis-related cerebral edema. J Pediatr. 2002 Dec; 141(6):793-7. View abstract
  93. Cellular activation, phagocytosis, and bactericidal activity against group B streptococcus involve parallel myeloid differentiation factor 88-dependent and independent signaling pathways. J Immunol. 2002 Oct 01; 169(7):3970-7. View abstract
  94. Development and validation of a multivariable predictive model to distinguish bacterial from aseptic meningitis in children in the post-Haemophilus influenzae era. Pediatrics. 2002 Oct; 110(4):712-9. View abstract
  95. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood. 2003 Feb 01; 101(3):831-6. View abstract
  96. Comparison of prediction models for adverse outcome in pediatric meningococcal disease using artificial neural network and logistic regression analyses. J Clin Epidemiol. 2002 Jul; 55(7):687-95. View abstract
  97. Extremity pain and refusal to walk in children with invasive meningococcal disease. Pediatrics. 2002 Jul; 110(1 Pt 1):e3. View abstract
  98. Fatal disseminated Candida lusitaniae infection in an infant with chronic granulomatous disease. Pediatr Infect Dis J. 2002 Mar; 21(3):262-4. View abstract
  99. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun. 2001 Aug; 69(8):4870-3. View abstract
  100. Meningococcal disease among children who live in a large metropolitan area, 1981-1996. Clin Infect Dis. 2001 Apr 01; 32(7):1004-9. View abstract
  101. Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. N Engl J Med. 2001 Jan 25; 344(4):264-9. View abstract
  102. Antibiotic treatment of children with unsuspected meningococcal disease. Arch Pediatr Adolesc Med. 2000 Jun; 154(6):556-60. View abstract
  103. Endocarditis caused by Corynebacterium diphtheriae: case report and review of the literature. Pediatr Infect Dis J. 2000 Feb; 19(2):159-63. View abstract
  104. Primary respiratory syncytial virus infection: pathology, immune response, and evaluation of vaccine challenge strains in a new mouse model. Vaccine. 2000 Jan 31; 18(14):1412-8. View abstract
  105. Carcinogen-modified dendritic cells induce immunosuppression by incomplete T-cell activation resulting from impaired antigen uptake and reduced CD86 expression. Immunology. 2000 Jan; 99(1):16-22. View abstract
  106. Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretions. Pediatr Infect Dis J. 2000 Jan; 19(1):1-7. View abstract
  107. Treatment of severe pertussis: a study of the safety and pharmacology of intravenous pertussis immunoglobulin. Pediatr Infect Dis J. 1999 Jun; 18(6):505-11. View abstract
  108. Necrotizing fasciitis of the pharynx following adenotonsillectomy. Int J Pediatr Otorhinolaryngol. 1999 Apr 25; 48(1):1-7. View abstract
  109. Clinical and hematologic features do not reliably identify children with unsuspected meningococcal disease. Pediatrics. 1999 Feb; 103(2):E20. View abstract
  110. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis. 1998 Dec; 178(6):1555-61. View abstract
  111. Cerebrospinal fluid pleocytosis and prognosis in invasive meningococcal disease in children. Pediatr Infect Dis J. 1998 Oct; 17(10):855-9. View abstract
  112. Anticapsular polysaccharide antibodies and nasopharyngeal colonization with Streptococcus pneumoniae in infant rats. J Infect Dis. 1998 Sep; 178(3):878-82. View abstract
  113. Minimum protective serum concentrations of pneumococcal anti-capsular antibodies in infant rats. J Infect Dis. 1998 Apr; 177(4):986-90. View abstract
  114. Multivariable predictive models for adverse outcome of invasive meningococcal disease in children. J Pediatr. 1996 Nov; 129(5):702-10. View abstract
  115. Psychologic and physiologic reactivity to stressors in eating disordered individuals. Psychosom Med. 1988 Nov-Dec; 50(6):591-9. View abstract